CROMSOURCE
Private Company
Funding information not available
Overview
CROMSOURCE, now branded as ClinChoice, is a well-established, privately-held global CRO with nearly three decades of experience in the clinical research services sector. The company leverages its deep expertise in high-need therapeutic areas like oncology and rare diseases to offer a full suite of services from early-phase studies to post-marketing surveillance. Headquartered in Raleigh, North Carolina, it operates globally, providing strategic and operational support to accelerate client product development. As a service provider, its success is tied to the broader R&D spending of the biopharma industry, positioning it in a stable and growing market segment.
Technology Platform
Integrated suite of clinical trial services, methodologies, and technology-enabled solutions (EDC, CTMS, risk-based monitoring, data analytics) focused on therapeutic-area expertise in oncology, rare disease, and neuroscience.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
ClinChoice operates in a highly competitive global CRO market dominated by large public companies like IQVIA, ICON, and Labcorp. It also competes with other full-service private CROs and a multitude of niche service providers. Differentiation is achieved through deep therapeutic expertise, personalized service for mid-sized and biotech clients, and a focused operational approach in complex disease areas.